| Net Cash Provided by (Used in) Operating Activities |
-25.3K |
USD |
+81.9% |
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Financing Activities |
60K |
USD |
-78.7% |
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Investing Activities |
-42.2K |
USD |
+63.1% |
Q1 2025 |
Q1 2025 |
| Common Stock, Shares Authorized |
10M |
shares |
0% |
Q2 2025 |
Q2 2025 |
| Common Stock, Shares, Issued |
1.62M |
shares |
0% |
Q2 2025 |
Q2 2025 |
| Common Stock, Par or Stated Value Per Share |
0 |
USD/shares |
0% |
Q2 2025 |
Q2 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
-20K |
USD |
-148% |
Q1 2023 |
Q1 2023 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
6.52K |
USD |
-96.9% |
Q2 2025 |
Q2 2025 |
| Deferred Tax Assets, Valuation Allowance |
326K |
USD |
|
Q2 2025 |
Q2 2025 |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent |
0.21 |
pure |
0% |
Q1 2025 |
Q1 2025 |
| Deferred Tax Assets, Gross |
326K |
USD |
+61.2% |
Q2 2025 |
Q2 2025 |
| Deferred Income Tax Expense (Benefit) |
145K |
USD |
+293% |
Q1 2024 |
Q1 2024 |
| Additional Paid in Capital |
1M |
USD |
|
Q1 2023 |
Q1 2023 |
| Deferred Tax Assets, Net of Valuation Allowance |
145K |
USD |
|
Q4 2023 |
FY 2024 |